PROCEPT BioRobotics Corp
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
PRCT$23.05+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows F-
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities: | |||
| Net loss | $(95,572) | $(91,413) | $(105,897) |
| Adjustments to reconcile net loss to cash used in operating activities: | |||
| Depreciation and amortization | 6,390 | 5,234 | 3,807 |
| Stock-based compensation expense | 47,603 | 31,840 | 19,134 |
| Change in fair value in derivative liability | — | 114 | 107 |
| Non-cash lease adjustment | (508) | (383) | 13 |
| Provision for credit losses | 219 | 840 | — |
| Inventory write-down | 565 | 1,881 | 995 |
| (Gain) loss on foreign currency transactions | 157 | — | — |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (898) | (35,960) | (33,103) |
| Inventory | (14,498) | (17,235) | (9,751) |
| Prepaid expenses and other current assets | (1,102) | (3,211) | 1,051 |
| Other assets | (2,895) | (1,637) | (868) |
| Accounts payable | 6,648 | (2,152) | 5,789 |
| Accrued compensation | 1,590 | 4,652 | 3,438 |
| Accrued interest expense | 142 | 134 | 125 |
| Loan facility liability | (2,000) | — | — |
| Deferred revenue | 3,306 | 3,716 | 3,317 |
| Reimbursements for leasehold improvements from operating leases | — | 2,596 | 4,989 |
| Other liabilities | 1,868 | 1,771 | (1,149) |
| Net cash used in operating activities | (48,985) | (99,213) | (108,003) |
| Cash flows from investing activities: | |||
| Purchases of property and equipment | (9,356) | (4,409) | (25,206) |
| Net cash used in investing activities | (9,356) | (4,409) | (25,206) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock under employee stock purchase plan | 6,362 | 4,527 | 3,610 |
| Proceeds from issuance of common stock from the exercise of stock options, net | 4,831 | 11,075 | 2,480 |
| Proceeds from issuance of common stock, net of issuance costs | — | 164,523 | 161,705 |
| Net cash provided by financing activities | 11,193 | 180,125 | 167,795 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | (74) | — | — |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (47,222) | 76,503 | 34,586 |
| Cash, cash equivalents and restricted cash | |||
| Beginning of the period | 336,763 | 260,260 | 225,674 |
| End of the period | $289,541 | $336,763 | $260,260 |
| Reconciliation of cash, cash equivalents and restricted cash to balance sheets: | |||
| Cash and cash equivalents | $286,503 | $333,725 | $257,222 |
| Restricted cash | 3,038 | 3,038 | 3,038 |
| Cash, cash equivalents and restricted cash in balance sheets | $289,541 | $336,763 | $260,260 |
| Supplemental cash flow information | |||
| Interest paid | $3,463 | $3,970 | $4,056 |
| Non-cash investing and financing activities | |||
| Property and equipment included in accounts payable and accrued expenses | $969 | $348 | $1,863 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.